

**Apollo Life Sciences Holdings (Pty) Limited**  
**BALANCE SHEET AS AT MARCH 31, 2023**

	Note No.	Amount in ZAR 31-Mar-23	Amount in ZAR 31-Mar-22
<b>A ASSETS</b>			
<b>I Non-current assets</b>			
(a) Property, plant and equipment		-	-
(b) Intangibles assets under development		-	161,988
<b>Total non-current assets</b>		<b>-</b>	<b>161,988</b>
<b>II Current assets</b>			
(a) Inventories	1	-	-
(b) Financial assets			
(i) Trade receivables	2	-	24,039
(ii) Cash and cash equivalents	3	28,346	137,089
(c) Other current assets	4	112,991	80,980
<b>Total current assets</b>		<b>141,337</b>	<b>242,108</b>
<b>TOTAL ASSETS</b>		<b>141,337</b>	<b>404,096</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	5	100	100
(b) Other equity	6	(1,124.30)	(412,269)
<b>Total Equity</b>		<b>(1,024.30)</b>	<b>(412,169)</b>
<b>II Liabilities</b>			
<b>1 Non-current liabilities</b>			
(a) Other non-current liabilities	7	55,199	202,825
<b>Total non-current liabilities</b>		<b>55,199</b>	<b>202,825</b>
<b>2 Current liabilities</b>			
(a) Financial liabilities			
(i) Trade payables	8	16,083	169,838
(ii) Other financial liabilities	9	71,080	443,603
<b>Total current liabilities</b>		<b>87,163</b>	<b>613,440</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>141,337</b>	<b>404,096</b>

**Apollo Life Sciences Holdings (Pty) Limited**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023**

Amount in ZAR

Particulars	Note No.	31-Mar-23	31-Mar-22
<b>1</b> Revenue from operations	10	4,321	(64,272)
<b>2</b> Other Income	11	-	682,545
<b>3 Total Revenue (1+2)</b>		<b>4,321</b>	<b>618,273</b>
<b>4 Expenses</b>			
(a) Purchases of stock in trade		4,321	59,004
(b) Employee benefits expense	12	-	-
(c) Finance costs	13	1,124	1,393
(d) Other expenses	14	-	22,794
<b>Total expenses</b>		<b>5,445</b>	<b>83,190</b>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>(1,124)</b>	<b>535,083</b>
<b>6</b> Exceptional Item		-	-
<b>7 Profit / (Loss) before taxes (5+6)</b>		<b>(1,124)</b>	<b>535,083</b>
<b>8 Tax Expense:</b>			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
<b>9 Profit / (Loss) for the year after tax</b>		<b>(1,124)</b>	<b>535,083</b>

**Apollo Life Sciences Holdings (Pty) Limited**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED MARCH 31, 2023**

**(A) Equity share capital**

Particulars	Amount in ZAR
<b>Balance as at March 31, 2022</b>	<b>100</b>
Changes in equity share capital during the year	-
<b>Balance as at March 31, 2023</b>	<b>100</b>

**(B) Other equity**

Amount in ZAR

Particulars	Money pending allotment	Reserves and Surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
<b>Balance as at March 31, 2022</b>		<b>(1,024)</b>	-	<b>(1,024)</b>
Profit/loss for the year	-	(1,124)	-	(1,124)
Dividends		-	-	-
<b>Total comprehensive income</b>	-	<b>(1,124)</b>	-	<b>(1,124)</b>
<b>Balance as at March 31,2023</b>	-	<b>(2,149)</b>	-	<b>(2,149)</b>

Apollo Life Sciences Holdings (Pty) Limited  
Notes forming part of financial statement

Note

No.

1 Inventories	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
Finished goods	-	-
<b>Total</b>	-	-

2 Trade receivables	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
<b>Unsecured</b>		
Considered good	-	348,154
Considered doubtful	-	-
	-	348,154
Less: Allowance for doubtful trade receivables	-	-
<b>Total</b>	-	<b>348,154</b>

3 Cash and cash equivalents	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
Balances with banks:		
In current accounts	28,346	1,000
<b>Total</b>	<b>28,346</b>	<b>1,000</b>

4 Other current assets	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
<b>Unsecured, considered good</b>		
Loans and advances to suppliers	100,000	-
Balances with government authorities:		
-Others	12,991	10,656
- Advance tax		
<b>Total</b>	<b>112,991</b>	<b>10,656</b>

5 Share capital	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
<b>Issued, subscribed and fully paid-up</b>		
Equity share capital	100	100
<b>Total</b>	<b>100</b>	<b>100</b>

6 Reserves and surplus	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
<b>Surplus in statement of profit and loss</b>		
Opening balance	-	(412,269)
Add: Profit / (Loss) for the year	(1,124)	640,087
Less: Equity dividend	-	(227,818)
<b>Closing balance</b>	<b>(1,124.30)</b>	<b>227,818</b>
<b>Total</b>	<b>(1,124.30)</b>	<b>227,818</b>

7 Other non current liability	Amount in ZAR	
Particulars	31-Mar-23	31-Mar-22
Prepaid rent liability	-	202,825
Advance from customer	55,199	60,168
<b>Total</b>	<b>55,199</b>	<b>202,825</b>

Apollo Life Sciences Holdings (Pty) Limited

Notes forming part of financial statement

8 Trade payables

Amount in ZAR

Particulars	31-Mar-23	31-Mar-22
Trade payable	16,083	11,194
<b>Total</b>	<b>16,083</b>	<b>11,194</b>

9 Other Current financial Liabilities

Amount in ZAR

Particulars	31-Mar-23	31-Mar-22
Provisions	71,080	85,523
Other payables:		
- Statutory remittances	-	-
<b>Total</b>	<b>71,080</b>	<b>85,523</b>

Apollo Life Sciences Holdings (Pty) Limited  
Notes forming part of financial statement

Note

No.

**10 Revenue from operations** **Amount in ZAR**

Particulars	31-Mar-23	31-Mar-22
Sale of Product	4,321	(64,272)
<b>Total</b>	<b>4,321</b>	<b>(64,272)</b>

**11 Other Income** **Amount in ZAR**

Particulars	31-Mar-23	31-Mar-22
Profit on sale of asset	-	682,545
<b>Total</b>	<b>-</b>	<b>682,545</b>

**12 Employee benefit expenses** **Amount in ZAR**

Particulars	31-Mar-23	31-Mar-18
Salaries and wages	-	-
Staff Welfare	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**13 Finance cost** **Amount in ZAR**

Particulars	31-Mar-23	31-Mar-22
Bank charges	1,124	1,085
<b>Total</b>	<b>1,124</b>	<b>1,085</b>

**14 Other Expenses** **Amount in ZAR**

Particulars	31-Mar-23	31-Mar-22
Legal & professional fees	-	40,637
<b>Total</b>	<b>-</b>	<b>40,637</b>